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Some academic economists disagree, however, arguing
that prospective economic modelling is better than infor-
mal opinion.
CONCLUSIONS: This study raises doubts about whether
pharmacoeconomics has yet had much impact on R&D
prioritization. If pharmacoeconomics is to succeed in guid-
ing firms towards developing cost effective new products
(i.e., ones delivering greater population health gains per
unit of cost than existing products), then firms may need
stronger incentives to use prospective cost-effectiveness
modeling in R&D decisions.
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A COST-MINIMIZATION ANALYSIS OF IRON 
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OBJECTIVES: To compare the costs of baseline standard
treatment course for iron deficiency anemia with differ-
ent Fe-content medicines.
METHODS: The model for non-complicated iron defi-
ciency anemia treatment was worked out by experts in
the field of hematology: a course of 200 mg Fe daily
for 28 days. There were 5 Fe-content medicines avail-
able in Moscow pharmacies conventionally named H, S,
T, F, G with the same suggested clinical effectiveness. Ac-
tive Fe amount per tablet, necessary mean dose of
drug, mean duration of course treatment, drug price were
taken into account. Data on medicine prices was calcu-
lated as a mean value according to price-lists of Moscow
pharmacies derived from the Internet on April, 20, 1999.
RESULTS: The table below shows the results of this cost-
minimization analysis.
CONCLUSION: The course of treatment for iron defi-
ciency anemia with F-drug that is the cheapest really is
the most expensive. Cost-saving courses are those with S
and G-drugs. Although it is traditionally used in Russia,
price per pack shouldn’t be an economical criteria for
choice of treatment.
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PATIENTS’ PERCEPTIONS OF THE OUTCOMES 
OF TREATMENT WITH TOPICAL NSAIDS, 
RUBIFACIANTS AND ORAL PAIN REMEDIES. A 
PROSPECTIVE STUDY OF MEDICINES 
AVAILABLE THROUGH
COMMUNITY PHARMACIES
McNaughton D, Libby G, MacDonald T
Medicines Monitoring Unit, Ninewells Hospital, Dundee, 
Scotland
OBJECTIVES: To examine patients’ attitudes to and expe-
riences of NSAIDs, Rubifaciants and oral pain remedies.
METHODS: Subjects were recruited in one of 30 phar-
macies in Scotland representing rural, semi-rural and ur-
ban environments. Subjects who had purchased an Over
the Counter medicine from one of three Topical NSAIDs,
three Rubifaciants or one of four oral pain remedies were
asked to participate in a questionnaire based study. The
questionnaire examined pain assessment pre and post
treatment, side effects experienced, patients’ expectations
of treatment, treatment outcomes, opinion about the rel-
ative merits of the three groups of medicines and demo-
graphic data about the purchaser. The questionnaires
were anonymous but identified the study pharmacy. In-
formation about the effectiveness of different rates of re-
cruitment was also obtained. After an initial emphasis on
pharmacist inducements, the study pharmacist was sta-
tioned in the pharmacies and achieved a high rate of re-
cruitment and returned questionnaires.
RESULTS: Of 430 questionnaires distributed, 302
(70.23%) were returned; 13 patients were excluded due to
spoiled questionnaires. Of the remaining 289 patients, 94
(32.5%) purchased Topical NSAIDs, 105 (36.6%) Rubifa-
ciants and 90 (31.1%) purchased oral remedies. There was
no significant difference between the three groups in pain
scores pre and post treatment (p  0.22). There was a dif-
ference in choice of treatment type by age (p  0.021) with
patients aged over 60 more likely to choose a Topical
NSAID. Those who suffered symptoms less than once a
week and those choosing a Topical NSAID were more
likely to be first time users of the study treatment (both p 
0.001). Those in the Topical NSAID group were also more
likely to report that they would definitely buy the product
again than those in the other treatment groups (p  0.014).
CONCLUSIONS: Initial findings demonstrate a very low
level of adverse events and a high rate of satisfaction par-
ticularly with Topical NSAIDs as represented by a greater
willingness to buy again.
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Indicators
Conventionally named drugs
H S T F G
Fe mg/tab 10 100 80 45 100
Equivalent daily dose
(200 mg daily) tab 20 2 3 5 2
Price per pack USD* 2.06 3.18 4.42 0.95 1.53
Tablet number per pack 100 50 30 10 30
Price per tablet USD 0.02 0.06 0.15 0.01 0.05
Cost per course of 
treatment (28 days) 11.5 3.56 12.38 13.3 2.86
USD 4
*Prices in rubles were converted into USD according to the Central Bank rate
on April 20, 1999
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OBJECTIVES: Global quality of life (QoL) is an individ-
ual’s overall evaluation of their quality of life, and can be
distinguished from the total QoL, which is an aggregate
composed of items from various instruments. Hyland et
al. have developed a new global quality of life scale (Hy-
land scale). The purpose of this study was to investigate
how the Hyland scale evaluates the perception of health
status in patients with asthma, and to compare the Hy-
land scale with generic and asthma-specific instruments.
METHODS: A total of 167 patients with chronic asthma
(age: 48  8 yr, 83 males) completed pulmonary function
testing, a measurement of their airway hyperresponsive-
ness, their dyspnea rating (Medical Research Council
dyspnea scale), and assessments of their anxiety and de-
pression (HADS; Hospital Anxiety and Depression Scale)
and assessments of their health status. The global QoL
was assessed using the Hyland scale, and the health sta-
tus was assessed using the SF-36 and the Living With
Asthma Questionnaire (LWAQ).
RESULTS: The score on the Hyland scale was normally
distributed (mean:[SD]:74[14]). The test-retest reliability
of the Hyland scale was found to be high (intraclass coef-
ficient  0.80), and mild correlations were noted be-
tween the Hyland scale and the Anxiety and Depression
on the HADS (Spearman’s rank correlation coefficient
[Rs]  0.28 and 0.40 respectively). The Hyland scale
had a moderate correlation with the LWAQ (Rs  0.20),
and had its strongest correlation with the General Health
(Rs  0.48) among the 8 subscales on the SF-36. The Hy-
land scale did not have any significant correlations with
the FEV1, peak expiratory flow rates, or the degree of
airway hyperresponsiveness. Multiple regression analysis
showed that the Hyland scale was affected by the Anxi-
ety on the HADS, but its cumulative coefficient of deter-
mination was very low (R2  0.02).
CONCLUSIONS: The Hyland scale had mild correla-
tions with generic and disease-specific measures, and did
not correlate well with clinical parameters. The Hyland
scale may give insight into other aspects of the health sta-
tus different from what generic and disease-specific in-
struments evaluate.
PTH8
POTENTIAL COST SAVINGS ASSOCIATED 
WITH ASTHMA DRUG THERAPIES 
USING INTEGRATED DRUG AND MEDICAL 
CLAIMS DATA
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Threets K, Maldonato D, Fulop G, Refowitz R
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OBJECTIVE: To evaluate the potential cost savings of
asthma drug therapy in helping reduce incurred health-
care expenses.
METHODS: We integrated 18 months of drug and med-
ical claims for 49,059 continuously eligible, unique indi-
viduals. Individuals were eligible for study inclusion if, in
the first 12 months, they received a medical diagnosis of
asthma (ICD-9  493) or filled an asthma-related drug
prescription. A total of 1,830 asthmatics were included in
the study after exclusions for those under age 6, those over
age 64, and those with chronic obstructive pulmonary dis-
ease. We compared total health costs by type of medica-
tion (controller vs. any/none and any vs. none) in the last 6
months after stratifying for age and comorbidity. 
RESULTS: Annualized total health care costs were con-
sistently lower for those on controller medications than
those not on controller medications. The difference was
most noticeable for asthmatics on controller medications
who were 40–64 years old (n  261); these individuals
had an average annual expense of $5,961 versus $10,138
for those who were not on controller medications (n 
258) (p  .07). The relationship between the use of any
asthma medication and costs was inconsistent. While the
differences in cost for those under the age of 18 and over
the age of 39 were insignificant, there was a significant
difference among individuals between the ages of 18–39
who had lower comorbidity scores. Those individuals on
any asthma medication (n  176) had an average annual-
ized expense of $1,400 in the follow-up period, versus
$4,143 among those who were not on these medications
(n  52) (p  .0022).
CONCLUSION: Our study seems to confirm the findings
of others, suggesting that the use of controller medica-
tions, may reduce total health care costs. We plan now fur-
ther research to evaluate the effects of patient drug utiliza-
tion on these cost outcomes.
PTH9
RETROSPECTIVE OUTCOMES ANALYSIS OF 
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OBJECTIVES: This study analyzed managed care claims
to find out how zafirlukast, a recently established oral
asthma therapy, is being prescribed in clinical practice
and to evaluate the effects of zafirlukast therapy on
healthcare resource utilisation.
METHODS: We examined the claims of 780 patients
(12 years) who participated in a Northeastern US man-
aged care plan and had received at least 3 months’ therapy
with zafirlukast, including at least one repeat prescription.
Baseline medications were determined 3 months before the
start of zafirlukast. Use of healthcare services, including
number of outpatient visits, inpatient stays, emergency de-
partment visits, and asthma-related drug prescriptions,
were compared between 3 months before and 3 months af-
ter commencing zafirlukast.
RESULTS: Zafirlukast was prescribed to patients on a
variety of baseline medications, with 72% already receiv-
